Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger L Nation

Showing results (1-10 of 247) with videos related to

Pageof 25
Sort By:
Advances in Experimental Medicine and Biology|August 1, 2019
ConclusionRoger L Nation
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 7, 2017
Dose Suggestions for Intravenous Colistin in Pediatric Patients: Caution RequiredRoger L Nation
Advances in Experimental Medicine and Biology|August 1, 2019
Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic UseRoger L Nation, Alan Forrest
Seminars in Respiratory and Critical Care Medicine|December 21, 2007
Optimizing use of colistin and polymyxin B in the critically illRoger L Nation, Jian Li
The Journal of Antimicrobial Chemotherapy|April 28, 2006
Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosisJian Li, Roger L Nation
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2006
Old polymyxins are back: is resistance close?Jian Li, Roger L Nation
Current Opinion in Infectious Diseases|October 3, 2009
Colistin in the 21st centuryRoger L Nation, Jian Li
Pediatric Pulmonology|July 10, 2019
Optimization of dosing regimens of intravenous colistin in patients with cystic fibrosis: What data are required?Roger L Nation, Cornelia B Landersdorfer
Antimicrobial Agents and Chemotherapy|December 21, 2016
Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?Alexandre P Zavascki, Roger L Nation
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2016
Low doses of colistimethate: Don't rush in!Alexandre P Zavascki, Roger L Nation
Pageof 25

Showing results (1-10 of 247) with videos related to

Sort By:
Pageof 25
Advances in Experimental Medicine and Biology|August 1, 2019
ConclusionRoger L Nation
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 7, 2017
Dose Suggestions for Intravenous Colistin in Pediatric Patients: Caution RequiredRoger L Nation
Advances in Experimental Medicine and Biology|August 1, 2019
Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic UseRoger L Nation, Alan Forrest
Seminars in Respiratory and Critical Care Medicine|December 21, 2007
Optimizing use of colistin and polymyxin B in the critically illRoger L Nation, Jian Li
The Journal of Antimicrobial Chemotherapy|April 28, 2006
Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosisJian Li, Roger L Nation
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2006
Old polymyxins are back: is resistance close?Jian Li, Roger L Nation
Current Opinion in Infectious Diseases|October 3, 2009
Colistin in the 21st centuryRoger L Nation, Jian Li
Pediatric Pulmonology|July 10, 2019
Optimization of dosing regimens of intravenous colistin in patients with cystic fibrosis: What data are required?Roger L Nation, Cornelia B Landersdorfer
Antimicrobial Agents and Chemotherapy|December 21, 2016
Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?Alexandre P Zavascki, Roger L Nation
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2016
Low doses of colistimethate: Don't rush in!Alexandre P Zavascki, Roger L Nation
Pageof 25